Basilea Pharmaceutica AG
BPMUF
$54.00
$1.172.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 69.23M | 70.29M | 40.51M | 41.90M | 39.40M |
| Total Other Revenue | 6.07M | 6.16M | 1.67M | 1.73M | 1.67M |
| Total Revenue | 75.30M | 76.45M | 42.18M | 43.63M | 41.07M |
| Cost of Revenue | 36.50M | 37.06M | 28.60M | 29.57M | 41.32M |
| Gross Profit | 38.80M | 39.39M | 13.59M | 14.05M | -256.40K |
| SG&A Expenses | 9.09M | 9.23M | 8.33M | 8.61M | 8.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.59M | 46.29M | 36.92M | 38.19M | 50.31M |
| Operating Income | 29.71M | 30.17M | 5.26M | 5.44M | -9.25M |
| Income Before Tax | 30.14M | 30.60M | 4.05M | 4.19M | -12.09M |
| Income Tax Expenses | -2.23M | -2.27M | -7.42M | -7.67M | -9.60K |
| Earnings from Continuing Operations | 32.37M | 32.87M | 11.47M | 11.86M | -12.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.37M | 32.87M | 11.47M | 11.86M | -12.08M |
| EBIT | 29.71M | 30.17M | 5.26M | 5.44M | -9.25M |
| EBITDA | 30.62M | 31.09M | 5.61M | 5.81M | -8.33M |
| EPS Basic | 2.68 | 2.72 | 0.95 | 0.98 | -1.01 |
| Normalized Basic EPS | 1.56 | 1.58 | 0.21 | 0.22 | -0.63 |
| EPS Diluted | 2.39 | 2.43 | 0.89 | 0.92 | -1.08 |
| Normalized Diluted EPS | 1.36 | 1.38 | 0.18 | 0.19 | -0.63 |
| Average Basic Shares Outstanding | 12.09M | 12.09M | 12.09M | 12.09M | 12.00M |
| Average Diluted Shares Outstanding | 13.89M | 13.89M | 13.82M | 13.82M | 12.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
